Novo Nordisk’s GLP-1 drug Wegovy expanded its label to include the metabolic disorder known as MASH. Analysts say there’s ...

Employers are projecting a median 10% increase in healthcare costs for 2026, driven largely by high claims and specialty drug ...

The Trump administration is directing the Department of Health and Human Services to identify about 26 “critical medicines.” ...

Hospital margins improved in June as revenue gains outpaced patient volume — but Kaufman Hall’s latest data shows that financial gaps between high- and low-performing organizations persist, with ...

Turn complex healthcare data into clear, context-rich insights that drive faster, smarter decisions.

Direct patient engagement by life sciences manufacturers is at an all-time high. I am not just referring to direct-to-consumer advertising. Manufacturers are increasingly engaging patients through ...

Small businesses are struggling with rising costs and tariffs, but many are still looking to maintain or increase health coverage, according to a recent report from Chase.

Noom recently launched a microdosing program for GLP-1s. However, some are concerned about the use of compounded GLP-1s in this program, as they are not FDA-approved.

Even with venture capital fundraising slowing down, Hatteras Venture Partners was able to close two new funds for investments in seed- and early-stage companies. We also have a recap of recent ...